Hospital groups creating company to make cheap generic drugs

January 18, 2018 by Linda A. Johnson

Several major not-for-profit hospital groups are trying their own solution to drug shortages and high medicine prices: creating a company to make cheaper generic drugs.

The plan, announced Thursday, follows years of shortages of generic injected medicines that are the workhorses of hospitals, along with some huge price hikes for once-cheap generic drugs. Those problems drive up costs for hospitals, require significant staff time to find scarce drugs or devise alternatives, and sometimes mean patients get suboptimal medications.

The not-for-profit drug company initially will be backed by four groups—Intermountain Health, Ascension and two Catholic systems, Trinity Health and SSM Health—plus the VA health system.

Together, the five groups include more than 450 hospitals and many other health facilities. More health systems could join soon.

Explore further: FDA enlists companies to head off drug shortages

Related Stories

FDA enlists companies to head off drug shortages

October 31, 2013
The Food and Drug Administration is announcing a new proposal designed to head off more shortages of crucial medications that have disrupted care at hospitals and health clinics nationwide.

FDA takes steps to boost generic competition, limit prices

June 27, 2017
The Food and Drug Administration is taking steps to boost the number of generic prescription drugs in an effort to make medicines more affordable and to prevent price gouging.

As competition goes down, generic drug prices rise, study finds

July 3, 2017
If the cost of your generic prescription drug has risen, it may be due to a lack of competition among drug manufacturers, according to a University of Florida College of Pharmacy study.

States seek to expand lawsuit against generic drug-makers

October 31, 2017
Connecticut's attorney general and 45 of his colleagues are seeking to expand a federal antitrust lawsuit against generic drug-makers to include more manufacturers and medications, as well as senior executives at two companies.

US prices soaring for some generic drugs

November 13, 2014
(HealthDay)—Market forces are dramatically driving up the cost of some generic drugs, prompting U.S. investigations into the pricing of what should be cheap alternatives to brand-name medications.

Savings less than expected for generic oral chemotherapy

September 11, 2017
A study by researchers at the University of North Carolina Eshelman School of Pharmacy and Lineberger Comprehensive Cancer Center determined the cost savings for a generic version of an orally administered cancer treatment ...

Recommended for you

Researchers publish study on new therapy to treat opioid use disorder

May 22, 2018
Better delivery of medications to treat opioid use disorder (OUD) is key to addressing the opioid crisis and helping the 2.6 million Americans affected by the disease.

Could nonprofit drug companies cut sky-high prices?

May 17, 2018
(HealthDay)—Generic prescription drugs should be cheap, but prices for some have soared in the United States in recent years. Now a group of U.S. hospitals thinks it has a solution: a nonprofit drug maker.

Fewer antibiotics for kids, but more ADHD drugs

May 15, 2018
(HealthDay)—American kids are taking fewer prescription medications these days—but certain drugs are being prescribed more than ever, a new government study finds.

Opioid makers' perks to docs tied to more prescriptions

May 14, 2018
Doctors who accept perks from companies that make opioid painkillers are more likely to prescribe the drugs for their patients, new research suggests.

Less is more when it comes to prescription opioids for hospital patients, study finds

May 14, 2018
In a pilot study published in JAMA Internal Medicine, Yale researchers significantly reduced doses of opioid painkillers given to hospital patients. By delivering the opioids with a shot under the skin or with a pill instead ...

Generic options provide limited savings for expensive drugs

May 7, 2018
Generic drug options did not reduce prices paid for the cancer therapy imatinib (Gleevec), according to a Health Affairs study released today in its May issue.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.